The latest price target for Ascentage Pharma Group (NASDAQ:AAPG) was reported by BTIG on April 13, 2026. The analyst firm set a price target for $48.00 expecting AAPG to rise to within 12 months (a possible 76.60% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Ascentage Pharma Group (NASDAQ:AAPG) was provided by BTIG, and Ascentage Pharma Group reiterated their buy rating.

There is no last upgrade for Ascentage Pharma Group

There is no last downgrade for Ascentage Pharma Group.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ascentage Pharma Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ascentage Pharma Group was filed on April 13, 2026 so you should expect the next rating to be made available sometime around April 13, 2027.

While ratings are subjective and will change, the latest Ascentage Pharma Group (AAPG) rating was a reiterated with a price target of $48.00 to $48.00. The current price Ascentage Pharma Group (AAPG) is trading at is $27.18, which is out of the analyst’s predicted range.